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Executive Summary
 
Genital human papillomavirus (HPV) infection is the most common sexually transmitted disease 
(STD) in the United States and is of increasing public health concern, yet no prevention programs 
have been established. Certain HPV types cause abnormal Pap smears and are etiologically related 
to cervical, vulvar, anal, and penile cancers; other types cause genital warts, recurrent respiratory 
papillomatosis, and low-grade Pap smear abnormalities. Recommendations for programmatic ac­
tivities, prevention research, and evaluation were developed by a group of invited experts who met 
in Atlanta on April 13-14, 1999. This consultation on “Prevention of Genital HPV Infection and 
Sequelae” was cosponsored by CDC’s Division of STD Prevention (DSTD), National Center for 
HIV, STD, and TB Prevention (NCHSTP); Division of Cancer Prevention and Control (DCPC), Na­
tional Center for Chronic Disease Prevention and Health Promotion (NCCDPHP); Division of Viral 
and Rickettsial Diseases (DVRD), National Center for Infectious Diseases (NCID); and the Ameri­
can Cancer Society (ACS). Discussions were focused around key questions for seven topics perti­
nent to prevention of genital HPV infection and sequelae: the role of HPV testing in cervical cancer 
screening, cancer screening in adolescents, non-vaccine approaches to primary prevention of HPV 
infection, preparedness for prophylactic HPV vaccines, public and provider awareness, prevention 
of anal cancer, and surveillance for HPV and cancer. Following a summary of the discussion of the 
issues in each core topic area, recommendations are listed. These include recommendations (sum­
marized below) for programmatic public health/prevention activities ready for implementation in 
the near future as well as recommendations for prevention research or other evaluation activities. 
While these recommendations were made primarily as suggestions for CDC and ACS, many are 
also relevant for other organizations interested in prevention of genital HPV or related sequelae 
(e.g., the National Institutes of Health). The intent of this report is to stimulate long-term collabora­
tive efforts among a variety of organizations. 
Summary of Recommendations for Public Health/Prevention 
Activities for Genital HPV Infections and Sequelae 
1.	 Role of HPV testing in cervical cancer screening 
a.	 CDC and ACS should acknowledge usefulness of HPV testing as an option in triage of 
women with ASCUS Pap smears. 
b.	 CDC or ACS should facilitate a meeting to review cervical cancer prevention modeling 
and assess cost-effectiveness of different strategies. 
2.	 Cervical cancer screening in adolescents 
a.	 Because the large majority of cervical lesions in adolescents are self-limited, in those with 
low-grade cytologic abnormalities (e.g., ASCUS, LSIL) consideration should be given to 
conservative follow-up by repeat Pap smear rather than triage by HPV testing or early 
colposcopy/biopsy. 
b.	 CDC and ACS should recommend that the cytology should be collected first when Pap 
smear screening is conducted concurrently with STD testing. 
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3. Non-vaccine modalities for primary prevention of genital HPV infection 
a.	 Given the uncertainties about prevention of transmission of genital HPV to sexual 
partners, a standard script for providers to use in education /counseling should be devel­
oped and used. 
4.	 Preparedness for prophylactic HPV vaccines - none ready for implementation. 
5.	 Provider, patient, and public awareness 
a.	 CDC, ACS, and other professional organizations should draft and disseminate a consen­
sus statement for use in professional educational materials of what has been scientifically 
established about genital HPV (as well as what is not known). 
b.	 In conjunction with provider materials, patient educational materials should be developed 
and distributed. 
6.	 Anal Cancer - none ready for implementation. 
7.	 Surveillance for genital HPV infection and sequelae 
a.	 Routine disease reporting of all genital HPV infections or for any specific types is not rec­
ommended at this time. 
b.	 CDC should conduct further analysis of the experience with genital warts reporting in 
various states to guide future directions in genital warts surveillance. 
c.	 Because routine reporting of CIS could be a useful adjunct to cancer surveillance, espe­
cially as HPV vaccine programs are implemented, problems encountered by SEER in the 
past should be examined and alternative approaches considered. 
d.	 Surveillance for HPV-related cancers should be enhanced in ways that contribute to un­
derstanding the causative role of HPV infection and prevention strategies (e.g., special 
studies using population-based cancer registries to ascertain sexual preference for men 
with anogenital cancers). 
Summary of Research/Evaluation Priorities for Prevention of 
Genital HPV Infections and Sequelae 
1.	 Role of HPV testing in cervical cancer screening 
a.	 demonstration projects to evaluate feasibility/cost-effectiveness of HPV testing for triage 
(high priority) 
b.	 HPV testing for triage in targeted high-risk populations (high priority) 
c.	 HPV testing in primary screening in developed countries (high priority) 
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d.	 HPV testing in primary screening in developing countries (high priority) 
e.	 HPV testing in follow-up of untreated CIN 1 and treated CIN 2/3 (intermediate priority) 
2.	 Cervical cancer screening in adolescents 
a.	 natural history of CIN 2 (prospective) and CIN 3 (comparative laboratory studies) in 
adolescents (high priority) 
b.	 long-term reproductive complications of ablative therapy in adolescents (high priority) 
c.	 long-term behavioral complications of ablative therapy in adolescents (intermediate 
priority) 
d.	 feasibility of recommending initiating Pap smear screening based on coitarche 
(intermediate priority). 
e.	 relative importance of rapidly progressive cancer in younger women (low priority) 
3.	 Non-vaccine modalities for primary prevention of genital HPV infection 
a.	 assessment of HPV endpoints in ongoing condom and microbicide studies of STD/HIV 
prevention (high priority) 
b.	 efficacy of promotion of behavior change (reduction of partner number, etc.) to prevent 
HPV (high priority) 
c.	 definition of laboratory markers of genital HPV infectiousness (intermediate priority) 
d.	 benefit of treatment in preventing HPV transmission (intermediate priority) 
e.	 assessment of risk factors for persistent HPV infection and its role in transmission (interme­
diate priority) 
4.	 Preparedness for prophylactic HPV vaccines 
a.	 assessment of rates and risk factors for HPV incidence, prevalence, and persistence in 
men (high priority) 
b.	 development of better sampling/ testing methods for incident HPV infection, including 
self-sampling (high priority) 
c.	 marketing research among the general public and providers about HPV vaccine accept­
ability (high priority) 
d.	 modeling studies of HPV transmission to target immunization programs (high priority) 
e.	 cost-effectiveness studies of HPV vaccines, including types 6/11(high priority) 
f.	 studies of more convenient routes of delivery and dosing schedules of HPV vaccines (high 
priority) 
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g.	 following efficacy trials, immunogenicity studies in other groups (men, young teens, STD 
clinics) (high priority) 
h.	 following licensure, studies of behavioral impact of vaccine use (high priority) 
5.	 Provider, patient, and public awareness 
a.	 surveys of provider knowledge, attitude, and practices (intermediate priority) 
b.	 assessment of counseling/education needs of patients/partners and alternative methods 
(high priority) 
c.	 determination of psychosocial impact of diagnoses of HPV and of disclosure to partners 
(intermediate priority) 
d.	 surveys of knowledge and attitudes of the general public (intermediate priority) 
e.	 pilot public education programs to assess optimal form and content and drawbacks of 
messages (high priority) 
6.	 Anal cancer prevention 
a.	 multicenter study of natural history and effectiveness/complications of therapy of anal 
LSIL and HSIL (high priority) 
b.	 anal Pap smear reproducibility, interobserver variability, optimal sampling technique, 
predictive value (high priority) 
c.	 assessment of role of HPV testing in anal cancer screening and triage of abnormal Pap 
smears (intermediate priority) 
d.	 assessment of risk factors for anal cancer in women and heterosexual men (intermediate 
priority) 
7.	 Surveillance for genital HPV infection and sequelae 
a.	 population-based serosurveys enhanced by collection of mucosal swabs for DNA 
detection (high priority) 
b.	 sentinel approach for surveillance of HPV-related disease (high priority) 
c.	 enhance surveillance for JORP to better understand risk factors for transmission (high 
priority) 
d.	 expand/redefine ICD and CPT codes to capture better data on HPV-related procedures 
(intermediate priority) 
e.	 collaborate with organizations with electronic clinic databases to monitor genital warts 
trends (intermediate priority) 
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Introduction
 
Genital human papillomavirus (HPV) infections are sexually transmitted infections of increasing 
public health importance. Known for years as the cause of genital warts, there is a growing body of 
evidence demonstrating the etiological association with a variety of anogenital cancers. Further­
more, genital HPV infections are widespread among adults who have been sexually active and are 
estimated to have the highest incidence of any sexually transmitted disease (STD) in the U.S.1. Al­
though cervical cancer screening programs have been implemented in the U.S. and other devel­
oped countries for decades, public health agencies have not established programs for primary 
prevention of genital HPV infection nor attempted to modify existing cancer prevention programs 
to take advantage of the associated role of HPV2. 
With the steady progress being made against bacterial STD and the increasing recognition of the 
widespread prevalence of viral STD such as genital herpes and genital HPV infection, the Centers 
for Disease Control and Prevention (CDC) has initiated a Viral STD Prevention Initiative to system­
atically evaluate possible control strategies and a prevention research agenda for these infections. 
As part of this process, CDC’s Divisions of STD Prevention (DSTD), Cancer Prevention and Control 
(DCPC), and Viral and Rickettsial Diseases (DVRD) and the American Cancer Society (ACS) 
co-sponsored an expert consultants’ meeting on April 13-14, 1999 on “Prevention of Genital HPV 
Infection and Sequelae”. Invited participants included 36 external consultants and 24 participants 
from CDC or ACS with expertise in the biology and epidemiology of HPV, clinical management, 
laboratory sciences, behavioral sciences, health education, health services research, and STD and 
cancer prevention program implementation and development. The meeting was organized around 
three workgroups during which participants discussed key questions in seven selected core topic ar­
eas pertinent to prevention of genital HPV infection and sequelae: the role of HPV testing in cervi­
cal cancer screening, cancer screening in adolescents, non-vaccine approaches to primary 
prevention of HPV infection, preparedness for prophylactic HPV vaccines, public and provider 
awareness, prevention of anal cancer, and surveillance for HPV and cancer. It should be noted that 
other important topic areas were not considered for specific workgroup discussion (e.g., increasing 
coverage of Pap smear screening in the population, treatment of HPV-related disease) because of 
lack of time and the perception that they would be more effectively addressed in other settings. 
This report is organized around the seven core topic areas and represents the collective delibera­
tions and recommendations from the workgroups and a concluding discussion session including all 
participants. Following a summary of the discussion of the issues in each core topic area, recom­
mendations are listed. These include recommendations for programmatic public health/prevention 
activities ready for implementation in the near future as well as recommendations for prevention re­
search or other evaluation activities. While these recommendations were made primarily as sugges­
tions for CDC and ACS, many are also relevant for other organizations interested in prevention of 
genital HPV or related sequelae (e.g., the National Institutes of Health). The future response to these 
recommendations will optimally be collaborative among a variety of organizations, and it is hoped 
that this report will serve as a stimulus for such long-term collaborative efforts. 
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Overview
 
Papillomaviruses are members of the papovaviridae family of DNA viruses, all of which are con­
sidered tumor viruses because of their ability to immortalize normal cells. They are species-specific 
and occur in a wide variety of vertebrates, where they cause benign and malignant epithelial prolif­
erations. Because papillomaviruses complete their life cycle only in fully differentiated epithelial 
cells, they are difficult to propagate in cell culture, which has limited the study of their life cycle, im­
munology, transmission dynamics, diagnosis, and therapy. The initial lack of well-characterized vi­
ral antigens also means that, in contrast to most other viruses, papillomavirus taxonomy is based on 
DNA homology rather than antigenic diversity3, 4. For HPV, more than 100 different types have 
been detected, over 80 of which have been well-characterized by genomic sequencing, with differ­
ent types defined as having < 90% homology with DNA sequences of L1 (HPV Nomenclature 
Committee, 16th International Papillomavirus Conference, Quebec, 1998). Approximately 30 types 
cause infection of genital mucosal sites, and these genital types are generally characterized as 
“high-risk” types (e.g., HPV 16, 18, 31, 33, 35, 39, 45, 51, 52), which are associated with low- and 
high-grade squamous intraepithelial lesions (LSIL and HSIL) and invasive cancer, and “low-risk” 
types (e.g., HPV 6, 11, 42, 43, 44), which are primarily associated with genital warts, LSIL, and re­
current respiratory papillomatosis (RRP)3-6. 
The sequela of genital HPV infection of greatest public health importance is cervical cancer. For 
over a century, epidemiologic studies have indicated a relationship between cervical cancer and 
sexual activity, with consistent associations with age of onset of sexual activity, multiple sexual part­
ners, and contact to “high-risk” males, men with multiple partners or prior partners with genital 
neoplasia7-10. During the past 50 years, there have been ongoing attempts to identify a sexually 
transmitted agent responsible for these observations, and associations can be found with most sexu­
ally transmitted bacteria and viruses. Over the last 15 years, however, the central role of HPV in the 
pathogenesis of cervical cancer has been firmly established. High-risk types of HPV are found in > 
93% of cervical cancers worldwide, with HPV 16 present in 50% and HPV 18, 31, and 45 in an­
other 30%11, 12, and case-control studies from several areas have demonstrated odds ratios for HPV 
detection in cervical cancer of 15-466, 13. Furthermore, high-grade cervical intraepithelial neoplasia 
precursor lesions (e.g., CIN 2 and 3) have similarly high rates of the same HPV types (5, 6, 13, 14), 
and prospective studies have demonstrated a plausible temporal relationship, with infection with 
high-risk HPV types consistently preceding development of CIN 2/3 13, 15, 16). Finally, the 
epidemiologic data are supported by laboratory studies demonstrating that high-risk HPV types 
contain genomic sequences with oncogenic activity, E6 and E7, which are consistently retained and 
expressed in cancers. Integration of HPV into cellular DNA occurs in the majority of cancers. This 
event generally disrupts the HPV E2 transcription regulatory gene and enhances stability of HPV 
mRNA by attaching it to cellular sequences. Either of these events may lead to increased expression 
of the E6 and E7 proteins. They, in turn, affect cell growth by binding with cellular tumor suppres­
sion proteins, E6 with p53 and E7 with the retinoblastoma gene product, causing their inactivation 
and ultimately the disruption of normal cell cycle control3, 6, 17. 
This body of epidemiologic and laboratory data is sufficiently strong that the International 
Agency for Research on Cancer and the National Institutes of Health have concluded that high-risk 
genital HPV types act as carcinogens in the development of cervical cancer6, 18. While infection with 
high-risk types appears to be “necessary” for the development of cervical cancer, it is not “suffi­
cient” in that cancer does not develop in the vast majority of infected women6, 18, raising questions 
about other possible co-factors, including smoking, hormonal exposure (e.g., multiparity and 
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prolonged oral contraceptive use), nutritional deficiency, HLA haplotypes, other genital tract infec­
tions, and immunodeficiency, especially HIV infection6. The data supporting the role of HPV in 
other anogenital cancers are more limited, although a large proportion of anal, as well as a subset of 
vulvar, vaginal, and penile cancers are also associated with high-risk HPV6, 19-22. 
Because genital HPV infection is not a reportable condition, assessments of its magnitude are de­
rived by extrapolation from epidemiological studies measuring current infection by detection of 
HPV DNA, with the most sensitive method being the polymerase chain reaction (PCR) technique, 
and approximating lifetime infection by measuring HPV antibody in serologic assays. While results 
have varied by population studied and sampling and detection methods used, overall they indicate 
that among sexually active women, over 50% have been infected with one or more genital HPV 
types, approximately 15% have evidence of current infection, 50-75% of which is with high-risk 
types, and 1% have genital warts14, 23-26. These findings are supported by a recent study of incident 
HPV infection in young women, which documented a 36-month incidence rate of 43%26. Men have 
been less well-studied, in part because sites and methods of mucosal sampling are less well-stan­
dardized. Levels of current infection in men as measured by PCR appear to be similar to women14, 27, 
28, while levels of lifetime infection as measured by serum antibody appear to be lower in men, pos­
sibly related to gender differences in the development of antibody after infection24, 29. A recent as­
sessment of the magnitude of various STD in the U.S. estimated an annual incidence of genital HPV 
infection of 5.5 million and a prevalence of current infection (detectable HPV DNA) of 20 million1. 
The majority of infections with all types appear to be subclinical, detectable neither by physical 
exam nor cytology, but only by the use of HPV DNA detection tests14, 23. 
The disease burden created by genital HPV infection is high. Worldwide, there are estimated to 
be 400,000-500,000 cases of cervical cancer per year10, 22. Most cases occur in developing coun­
tries without cervical cancer prevention activities; however, even in industrialized countries, where 
rates have fallen by up to 75% since the introduction of Pap smear screening programs, the disease 
burden is still considerable10, 30. In the U.S., for example, incidence rates are currently 8.3/100,000, 
with approximately 14,000 cases and 5000 deaths annually, despite the performance of an esti­
mated 50 million Pap smears per year. In addition, as a result of these screening activities, an esti­
mated 2.5 million Pap smears with low-grade abnormalities (e.g., atypical squamous cells of 
undetermined significance–ASCUS, atypical glandular cells of undetermined significance–AGUS, 
and LSIL) and 200,000-300,000 Pap smears with HSIL are detected annually in the U.S. While 
these lesions cause no clinical morbidity apart from that resulting from treatment, their magnitude is 
important because of the health care costs they generate31, 32. Despite the absence of prevention 
programs, the incidence of other HPV-related cancers are 5-10 fold lower than that of cervical 
cancer33, with the exception of anal cancer in homosexual men, which was estimated to be 
12-35/100,000 prior to the onset of the AIDS epidemic and which may be higher now34, 35. Esti­
mates for genital warts are less precise than those for cancer because of the absence of case report­
ing and because they often recur after treatment; however, limited data suggest that in the U.S. 
incidence rates may be as high as 100 per 100,00036 with a prevalence of 1.4 million14. Finally, esti­
mates for RRP, a disease of both children and adults in which papillomas of the larynx and upper re­
spiratory tract cause hoarseness and respiratory obstruction, are similarly imprecise, with estimated 
incidence rates of 0.4 to 1.2 per 100,000 children37. Only limited attempts have been made to esti­
mate the annual cost burden of genital HPV infection in the U.S. Existing estimates range from $1.6 
billion to $6 billion, making genital HPV the second most costly STD after HIV infection; these esti­
mates do not include costs for management of RRP, indirect costs (i.e., lost time and wages), or in­
tangible costs (e.g., emotional pain, anxiety, disrupted relationships)31, 38, 39. 
Factors associated with genital HPV infection in women have been evaluated in a large number 
of cross-sectional studies. Although smoking, pregnancy, and use of oral contraceptives have been 
variably associated with genital HPV infection, the most consistent predictors have been various 
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parameters of sexual activity. The lifetime number of sex partners has been associated with both 
current and lifetime infection in most studies which have addressed this question24, 25, 29, 40-44. How­
ever, several reports have emphasized that number of partners in more recent timeframes is even 
more highly associated with current infection45-49 and that the number of partners of the sex part-
ner(s) is an additional risk factor26, 46. Studies in men are more limited, but they suggest similar asso­
ciations with sexual activity24, 29, 50. While non-sexual routes of transmission of genital HPV infection 
via fomites, non-sexual contact, or vertical transmission are plausible51 and supported by some but 
not all serological studies in children52-54, cervical HPV infection has been rarely detected in virginal 
females55-57, and it is generally accepted that most genital HPV infections are transmitted by sexual 
activity7, 14. Alternatively, the likely mode of transmission for RRP is upper respiratory tract exposure 
to infected genital mucosa, at the time of delivery in juvenile-onset disease and presumably through 
oral-genital sexual contact for adults58. 
Of importance, an increasing body of data suggests that the majority of type-specific genital HPV 
infections are only transiently detectable by DNA detection techniques. Most studies have noted an 
inverse relationship of age with infection as measured by detection of HPV DNA. Peak rates are 
found in women < 25 years old, which is speculated to result from clearance of infection over time 
in most women as an effective immunologic response is induced7, 14, 26, 45-48, 59-61. Although questions 
remain as to whether HPV infection which becomes non-detectable by PCR has completely re­
solved or may intermittently reactivate62-64, median duration of incident infection is reported to be 8 
months, with rates of persistence of only 30% after 1 year and 9% after 2 years26. Because women 
with persistent infection, especially those with high-risk types, are at greater risk for developing 
CIN15, 26, 40, 65 and CIN lesions which persist rather than regress16, defining determinants of persis­
tence is important in assessing which of the many women with HPV infection are at most risk of sub­
sequent sequelae. Studies to date suggest that infection with high-risk and multiple types of HPV 
and older age are associated with persistent infection26, 66 . 
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Recommendations From The Workgroups 
1. Role of HPV testing in cervical cancer screening 
Background 
With the recognition of the etiologic role of high-risk types of genital HPV infection in cervical 
cancer, there has been an intense focus on the use of HPV diagnostic tests in cervical cancer preven­
tion activities. Interest has focused primarily in three areas: triage of women with low-grade Pap 
smear abnormalities, primary screening, and follow-up of women with confirmed CIN. All three 
uses are based upon the association of high-risk HPV types with high-grade precursor lesions. Eval­
uations of these strategies have used both non-amplified and PCR-based testing, although the re­
cent development and FDA approval of a more sensitive signal amplification assay, Hybrid Capture 
II (HC-II, Digene), should enhance standardized evaluation of these strategies and make reproduc­
ible use in clinical settings more feasible. 
The most comprehensively evaluated area is HPV testing for triage of low-grade Pap smear ab­
normalities (e.g., ASCUS, AGUS, and LSIL). Although the majority of women with these cytologic 
findings have normal histology or lesions which are likely to regress (CIN 1), a minority (5-20%) will 
have CIN2/3, representing the majority of high-grade lesions in some settings67-69. Current manage­
ment recommendations for women with low-grade abnormalities offer several options, including 
follow-up Pap smear evaluation with colposcopy only for those with persistent abnormalities or im­
mediate colposcopy for all women31. Neither approach is ideal. Routine colposcopy is costly and 
generates a large number of unnecessary procedures, while the follow-up Pap smear approach 
may result in women being lost to follow-up and lower cost-effectiveness, and both approaches may 
produce anxiety pending completion of the evaluation31, 70-72. 
A third option, HPV testing with colposcopy only for those with high-risk types identified, has also 
been recommended “for physicians who understand its limitations”31, but has not been widely 
accepted72-76 because of variation of earlier generations of commercially available tests in sensitivity 
for detection of CIN2/3 (56-93%) and cost-effectiveness71, 77, 78. The current generation HC-II test 
has an expanded number of high-risk HPV types and a lower detection threshold for HPV DNA, giv­
ing it a level of sensitivity similar to that of PCR79. It uses a battery of probes to detect presence of any 
of a group of 13 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and any of a 
group of low-risk types (6, 11, 42, 43, 44); it does not allow identification of specific HPV types. 
Published reports of its performance67, 80, including the largest evaluation to date of HPV testing for 
triage67, demonstrate high sensitivity (approximately 90%) and acceptable specificity (40-65%) for 
detection of CIN2/3 for women with ASCUS; similar results have been found in women with 
AGUS68. Test specificity and positive predictive value for detecting CIN2/3 are lower in settings 
where the prevalence of HPV infection is higher, such as younger women or those with LSIL81-83. 
The strategy of obtaining a sample at the time of the initial Pap smear to save for possible HPV test­
ing is feasible using either liquid-based cytology media (PreservCyt fluid, Cytyc Corporation) or a 
vial of sample transport media specific for HPV testing. This allows “reflex HPV testing” (testing only 
the samples from women whose Pap smears are found to be abnormal) without a return visit67, 83, 84, 
although does require appropriate sample collection and storage procedures. The use of HPV test­
ing for triage is being further evaluated in two large ongoing randomized trials in the U.S. and the 
U.K. which are comparing the three management strategies and which should provide even more 
information on their relative clinical value 70, 85 . Because HPV testing for triage largely serves to 
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enhance cost-effectiveness of care and reduce patient anxiety70, 72, these RCTs will include cost-ef­
fectiveness analyses to complement those currently underway67. Potential anxiety generated by 
HPV testing (when a patient and her partner are told they have or have been exposed to an incur­
able STD) will need to be considered in both clinical use and cost-effectiveness analyses70, 72. 
HPV testing for primary cancer screening is a more complex issue, but one with potentially 
greater benefit. Used as an adjunct to the Pap smear, it has the potential of increasing sensitivity and 
specificity of primary screening, and, more importantly, enhancing cost-effectiveness by lengthen­
ing the screening interval and determining when screening can be stopped altogether, especially 
among older women70, 77, 86-88. Of even greater importance is the possibility that it could be an alter­
native to the Pap smear for accessing women not currently being reached by Pap smear screening. 
In developed countries, ease of collection via vaginal swab could facilitate screening in clinic settings 
where pelvic examinations are not routinely available or acceptable or in non-clinic-based settings 
by outreach workers70. In developing countries without Pap smear screening programs, intermittent 
or even once in a lifetime HPV testing might be more feasible and cost-effective than cytologic 
screening77, 89, although would require implementation of treatment programs for its benefit to be 
fully realized. By enhancing population coverage, both of these strategies could not only enhance 
cost-effectiveness, but also lead to a reduction in cervical cancer incidence and mortality77, 89. In the  
context of primary screening, several studies have reported enhanced sensitivity for detection of 
CIN2/3 when HPV testing is combined with cytology in comparison to cytology alone90, 91. There  are  
a number of ongoing studies of primary screening in developed and developing countries compar­
ing cytology, HPV testing, or both for detection of CIN 2/3, with several preliminary reports describ­
ing sensitivities of HC-II of > 85%92-95. These and other studies, especially those from ongoing 
RCTs87, should provide the additional data regarding positive and negative predictive value and 
optimal age for HPV testing needed to determine its value in primary screening71. 
Lastly, regarding the use of HPV testing to manage women with confirmed CIN, interest stems 
from natural history studies which indicate that persistent high-risk HPV infection predicts subse­
quent development of CIN 2/315, 65, 96-99, and from studies of women with treated CIN which indicate 
that persistent HPV is associated with recurrent CIN. Because the large majority of CIN 1 lesions re­
gress without treatment, their routine treatment is not recommended, although close follow-up is re­
quired when treatment is deferred74, 100. Determination of whether high-risk HPV types are present, 
and if so, whether they persist, may help select a group in whom closer follow-up and/or treatment 
may be most useful. Likewise, following ablative treatment of CIN, approximately 10-15% of 
women will experience a recurrence81, 101. Presence of high-risk types of HPV DNA is associated with 
recurrences, and follow-up HPV testing could enhance identification of those most likely to recur, al­
lowing more intensive follow-up71, 102-104. 
Workgroup Discussion 
The workgroup felt that while the ongoing large RCTs evaluating HPV testing for triage would 
provide the most useful data from which to make definitive recommendations about the relative 
value of the three management options, recent data on the performance of HC-II in the triage of 
women with ASCUS (and AGUS) supported its value in this setting. The workgroup also thought 
that there are insufficient data to recommend HPV testing routinely for other clinical purposes at 
present, although there was agreement that testing might be of great value in primary screening and 
other clinical settings and that studies evaluating these possibilities were priorities. It was noted that 
although there are no data to address the possibility that CIN 2/3 lesions presenting with ASCUS or 
LSIL cytology have a different (less aggressive) natural history than those presenting with HSIL, this 
possibility may influence the cost-effectiveness of HPV testing for triage of low-grade abnormalities. 
The ongoing RCTs should provide some insight into this question, which may also be amenable to 
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evaluation by studies of molecular markers in tissues (e.g., specific HPV type, copy number, physi­
cal state and transcriptional activity, as well as other markers as they are discovered). 
Recommendations for public health/prevention activities 
a.	 The potential usefulness of HPV testing as an option in the triage of women with ASCUS 
and AGUS Pap smears should be acknowledged by CDC and other organizations. Formal 
recommendations about the use of HPV testing in this setting should be made after ongoing 
RCTs have been completed. HPV testing for other purposes is not currently recommended. 
b.	 CDC, ACS, and/or other organizations interested in prevention of genital HPV infection 
and sequelae should facilitate a meeting to review cervical cancer prevention modeling and 
assess cost-effectiveness of different strategies. This meeting could contribute to inter­
change of ideas regarding different approaches and development of a unified model and of 
common instruments to collect data for model calibration to enhance consistency of model­
ing efforts. The meeting should also attempt to develop and distribute simple cost-effective­
ness modules for use by local programs. 
Research/evaluation priorities 
a.	 Demonstration projects should be initiated to evaluate feasibility and cost-effectiveness of 
HPV testing for triage of ASCUS Pap smears in various “real-world” settings. Such analyses 
should consider direct costs of providing counseling and education for patients who test 
HPV-positive and their partners, as well as indirect costs (e.g., lost wages and productivity) 
and intangible costs (e.g., anxiety, psychosocial burden of being diagnosed with HPV infec­
tion). (High priority) 
b.	 If ongoing RCTs confirm that HPV testing improves clinical management of women with 
ASCUS Pap smears, focused studies should be performed among high-risk women who 
may not be adequately represented in multicenter trials (e.g., STD and family planning clin­
ics, minority populations, HIV+ women, adolescents, older women). (High priority) 
c.	 Additional studies should be performed in U.S. populations to evaluate HPV testing as an 
adjunct to the Pap smear in primary screening for cervical cancer as a method of enhancing 
sensitivity and lengthening screening intervals. These should involve evaluation of self-col­
lected samples for HPV testing as a means of increasing coverage of screening programs in 
difficult-to-access populations and should be supplemented by modeling studies to assess 
cost-effectiveness. (High priority) 
d.	 Studies should be performed to evaluate HPV testing as a potentially cheaper and easier to 
implement alternative to cytology in developing countries that presently lack comprehen­
sive cervical cancer screening programs. (High priority) 
e.	 Studies should be performed to assess clinical utility of HPV testing in follow-up of women 
with untreated CIN 1 (i.e., more intensive follow-up and/or earlier treatment for those with 
persistent high-risk HPV infection) and following treatment of HSIL (as a test-of-cure). (In­
termediate priority) 
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2. Cervical cancer screening in adolescents 
Background 
Since the early 1980s, U.S. guidelines for cervical cancer prevention have recommended initiat­
ing Pap smear screening at age 18 or with the onset of sexual activity74, 105-107. In contrast, because 
the latency period of cervical cancer after onset of sexual activity is lengthy and rates of cervical can­
cer are very low in adolescents33, guidelines in various European countries recommend starting rou­
tine screening between the ages of 20 and 30 years. There are several arguments in favor of 
beginning screening in adolescence. Despite low cancer rates, there are indications that increasing 
sexual activity in adolescents has resulted in increased rates of CIN108, 109. There is also evidence that 
the incidence of cervical cancer has increased in younger women (<35 years old) in some 
countries108, 110-112, although the trend in the U.S. is less clear33, 113. Additionally, questions remain 
about a possibly increased risk in younger women of “rapidly progressive” lesions which can evolve 
over a much shorter time than the usual latency period114, 115. Finally, there are concerns that HPV 
transmission to pre-adolescents as a result of sexual activity or abuse could be underestimated and 
represent an important problem57, 116, 117 . 
On the other hand, initiating screening at such a young age raises several problems116, 118-121. First, 
screening in adolescents is likely to be less cost-effective than in older women, both because the de­
velopment of high-grade lesions within the first several years after the onset of intercourse is infre­
quent and because the latency period of those which do occur is generally long enough to allow 
their detection if screening is initiated in the early-mid 20s30, 107. Furthermore, modeling studies sug­
gest that CIN has a higher probability of regression in younger than older women122, which is likely a  
result of higher rates of recently acquired genital HPV infection in young women, whose manifesta­
tions are usually transient, in contrast to the greater likelihood of persistent infection in older 
women. These considerations suggest a greater potential for detecting transient low-grade abnor­
malities in younger women, which lead to additional unnecessary management costs89, 118, 122. Sec­
ond, there are concerns that adolescents may have a higher rate of post-treatment complications 
than older women, both physiologic and behavioral. Although the data regarding long-term effects 
of the therapeutic modalities for CIN in current widespread use (e.g., cryosurgery, LEEP, and laser) 
do not suggest an increase in problems related to fertility or pregnancy, the studies have had rela­
tively short follow-up periods and have been too small to evaluate age-specific outcomes123. One  re­
cent report of complications of cryosurgery in adolescents reported PID in 9%, cervical stenosis in 
3%, and cervical narrowing in 30%124. It has also been suggested that the anxiety engendered as a 
result of undergoing a pelvic exam or of being informed of a “pre-cancerous” Pap smear result may 
be greater in adolescents than in older women118, 119. 
Workgroup discussion 
The workgroup agreed that several questions were important to address regarding Pap smear 
screening of adolescents. It was not felt that current recommendations about age of onset of screen­
ing should be changed. However, because of the likelihood of a more benign natural history of CIN 
2/3 lesions and limited data on long-term complications in younger women, the workgroup felt that 
screening in adolescents may have low cost-effectiveness and thus bears reconsideration. There 
was consensus that it would be useful and ethical to learn more about the natural history of CIN 2 le­
sions in adolescent women and that, in young women in whom follow-up could be assured, it would 
be appropriate to follow such lesions without treatment in research settings. In those undergoing 
both Pap smear and STD testing, it was felt that bleeding induced by cervical swabs was potentially 
a greater problem for cytology than for cervical gonorrhea or chlamydia tests and that the Pap 
smear should be collected first. 
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Recommendations for public health/prevention activities 
a.	 Because the large majority of cervical lesions in adolescents are self-limited, in those with 
low-grade cytologic abnormalities (e.g., ASCUS, LSIL) consideration should be given to 
conservative follow-up by repeat Pap smear rather than triage by HPV testing (since predic­
tive value in adolescents is not well-characterized) or by early colposcopy/biopsy. 
b.	 CDC and ACS should recommend that the cytology sample be collected first when Pap 
smear screening is conducted simultaneously with STD testing. If STD tests are run on single 
samples collected as part of liquid-based cytology testing, sequence questions will not be an 
issue. 
Research/evaluation priorities 
a.	 Prospective studies of the natural history of untreated CIN 2 in adolescents should be 
performed in carefully monitored research settings. Although similar natural history studies 
of untreated CIN 3/CIS would be difficult to perform for ethical reasons, comparative 
molecular studies (e.g., specific HPV type, copy number, physical state and transcriptional 
activity, as well as other markers as they are discovered) of these lesions in younger versus 
older women would be useful in assessing possible differences in natural history. (High 
priority) 
b.	 Studies should be performed to better characterize the incidence and type of long-term 
reproductive complications of ablative therapy of CIN in adolescents. (High priority) 
c.	 Studies should be conducted to determine if the experience of undergoing ablative therapy 
of CIN influences future health-care seeking behavior of adolescents (e.g., makes them less 
likely to return for follow-up to avoid pain or complications). (Intermediate priority) 
d.	 Studies should be conducted to determine the feasibility of recommending initiation of Pap 
smear screening a certain number of years after acknowledged first sexual activity rather 
than at a specific age (e.g., determine rate of abnormality by years of stated activity, willing­
ness to discuss age of onset of sexual activity). (Intermediate priority) 
e.	 Multicenter studies should be performed comparing younger and older women with 
invasive cervical cancer to determine whether rapid onset disease is more common in 
younger women and, if so, to assess associated risk factors (e.g., HPV type, histologic type, 
age of onset of sexual activity, presence of other co-factors). (Low priority) 
3.	 Non-vaccine modalities for primary prevention of genital HPV infection 
Background 
The reproductive rate of a sexually transmitted infection in a susceptible population is a function 
of three parameters: the efficiency of transmission per sexual partnership, the duration of infectivity, 
and the number of new partners an infected person has per unit of time125, 126. In the absence of 
measures to reduce susceptibility (e.g., effective vaccines), strategies to reduce each of these 
parameters can reduce transmission of infection: the efficiency of transmission by strategies to re­
duce infectivity (e.g., condoms, microbicides), the duration of infectivity by treatment, and new 
partnerships by behavior change approaches. There is limited understanding about the value of 
each of these approaches for prevention of genital HPV infection. 
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Theoretically, barrier contraceptives such as condoms are less likely to be effective in preventing 
infections such as genital HPV, which can involve the external genital skin, than they are for 
infections which are limited to specific mucosal areas and spread by semen (e.g., chlamydia or 
gonorrhea), although estimation of potential benefit of condoms for HPV is hindered by absence of 
measures of infectivity. Studies which have attempted to assess male condom benefit for women 
have generally found no evidence of protection against infection26, 28, 43, 45, 46. However, existing 
reports have not adequately assessed consistency and correctness of condom use, and, in cross-sec­
tional studies, HPV infection may have preceded condom use. There are data suggesting a benefit 
of condom use for men, although the studies are limited29, 50 and no data available for female 
condoms for either women or men. Some reports have suggested a benefit in prevention of HPV-re­
lated disease (e.g., genital warts, SIL, cervical cancer)50, 127-130, possibly by reducing viral inoculum, 
repeated viral exposure, or exposure to other co-factors which might be involved in development of 
disease. However, a protective effect has not been seen consistently131, 132, and the cross-sectional 
and case control studies published to date are limited by recall bias and the difficulty in controlling 
for a variety of important variables132, 133. 
There are also reports of a potential protective effect of spermicides in the prevention of cervical 
cancer127, 128, 131, 132, which is of interest because of the microbicidal properties of such agents134. 
Evaluation of the activity of microbicides has been hampered by the difficulties with in vitro 
cultivation of HPV, which is needed to screen potential products. However, recent work with various 
papillomaviruses in animal systems indicates that while nonoxynol-9, which functions largely as a 
detergent that disrupts lipid envelopes, has no activity against non-enveloped viruses like 
papillomaviruses, other agents such as povidone-iodine and the detergent sodium dodecyl sulfate 
(SDS), which also denatures proteins, inactivate papillomaviruses including HPV135-137. Since SDS 
is a common ingredient in toothpaste and shampoo, it may be a promising agent for clinical trial 
evaluation in the future should human toxicity studies indicate lack of mucosal irritation with 
prolonged use. 
In contrast to bacterial STD, for which transmission can be prevented through curative treatment, 
there is no evidence that treatment of HPV-associated lesions is useful in prevention of transmis­
sion. There are no effective systemic therapies for genital HPV, as there are for bacterial and other vi­
ral STD, and current treatment options include a variety of locally destructive approaches for both 
genital warts and SIL, as well as topical use of cytotoxic and immunomodulating agents for genital 
warts138. It has been speculated that treatment of genital warts might be useful in reducing 
infectiousness138. This premise is difficult to test because of the lack of assays for infectivity, but is 
supported by observations that treatment of genital warts with the imunomodulating agent 
imiquimod reduces viral DNA and mRNA in post-treatment biopsies139 and that therapy of CIN 
results in clearance of HPV in follow-up cervical swabs in 70-80% of women102, 104. However, 
clinically normal skin and mucosa in the vicinity of HPV-associated lesions often contain HPV140, 141. 
This reservoir is thought to explain the typical recurrence rates of 10-20% after treatment for CIN81, 
103 and 20-50% after treatment of genital warts142 and the fact that treatment of partners does not 
influence recurrence rates of genital warts143. Thus, based on limited existing data, currently 
available therapies for HPV-related lesions may reduce but probably do not eliminate 
infectiousness, and whether the reduction in viral load which occurs with treatment impacts future 
transmission remains unclear. 
Workgroup discussion 
The workgroup agreed that existing data were not supportive of a benefit of male condoms, espe­
cially for women, but that because existing studies had serious methodologic limitations, an RCT 
would be the only study design by which the issue could be clarified. However, such a trial would be 
difficult and expensive to conduct, and because of the low probability of documenting benefit, a trial 
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specifically designed to evaluate the value of condoms for HPV prevention would not be a high 
priority. A more efficient approach would be to include HPV outcomes in prevention trials being 
undertaken for prevention of HIV or other STD, in which use of condoms or microbicides could be 
carefully documented. There was also agreement that comparison of the efficacy of existing 
treatments for genital warts, development of new therapies for genital warts and CIN, and a better 
understanding of the impact of existing and new therapies on transmission were important issues. 
Finally, there was extensive discussion about the merits of trying to reduce genital HPV transmis­
sion by focusing on behavior change approaches. As noted, the most consistent risk factor for HPV 
prevalence in cross-sectional studies and HPV incidence in observational studies is number of part­
ners and, secondarily, partners’ number of partners25, 28, 29, 40-49. It was pointed out that although 
HPV-related mortality is at least twice that of HIV for women in the U.S., the predominant STD/HIV 
prevention messages promoted are those pertaining to HIV risk reduction, and that, in contrast to 
HIV144, no attempts have been made to look at benefit of counseling strategies for HPV prevention. 
Since most women and men do not understand the prevalence of genital HPV infection or its role in 
cervical cancer, such knowledge might give them reasons to modify behavior. Increased awareness 
that HPV infection is widespread, that it might not be fully prevented by condom use, and that it can 
have rare but serious sequelae might help stimulate and sustain efforts to reduce exposure to HPV 
and other STD. Such strategies could include delay in initiation of sexual intercourse, a reduction in 
the number of partners, and selection of partners perceived to have had fewer partners. 
Options for prevention trials to evaluate the benefit of a behavior change approach could include 
individualized counseling or health education messages delivered at the community level, with a fo­
cus on the magnitude of genital HPV infection, its association with cancer, and the benefit of reduc­
ing partners and selecting less sexually experienced partners. However, concern was expressed 
that, although an intuitively promising approach, such a strategy would have a number of potential 
problems, including stigmatization and exaggerated fear about what would likely continue to be a 
very common STD, difficulty in using this approach for the large number of women in the popula­
tion with very few sex partners145, a likely increased emphasis on and requests for HPV tests, whose 
meaning would be difficult to interpret, and a potential to undermine condom use, possibly enhanc­
ing acquisition of other STD (e.g., HIV, gonorrhea) which are more effectively prevented by con­
dom use. 
Recommendations for public health/prevention activities 
a.	 Given the uncertainties about prevention of transmission of genital HPV to sexual partners, 
promulgation of a “standard script” for providers to use in education/counseling of patients 
with HPV infection (e.g., genital warts or CIN) would be helpful. Key messages should in­
clude the following: 
Persons with genital warts or CIN should be informed about the high prevalence 
of HPV infection among adults who have been sexually active and the likely 
persistence of infection after treatment for an indefinite period of time. 
Those with monogamous partners should be counseled that partners may 
already have been infected. 
No scientific data support condom use specifically for genital HPV prevention; 
however, condoms should be recommended for prevention of other STDs. 
Because duration of infectiousness is unknown and because genital HPV is so 
common among persons who have been sexually active, the value of disclosing a 
past diagnosis of HPV infection to future sex partners is unclear, although candid 
discussions about past STD should be attempted whenever possible. 
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Given the complexity of counseling messages, clinicians should be encouraged to 
refer patients to educational materials, hotlines, and other appropriate resources. 
Research/evaluation priorities 
a.	 Randomized clinical trials designed specifically to assess prevention of genital HPV infec­
tion by male and female condoms in both women and men would be desirable; however, 
these will be difficult and expensive to perform. Thus, attempts should be made to include 
HPV outcomes (e.g., incident infection defined by HPV DNA detection in mucosal samples 
or by seroconversion; development of cervical SIL lesions) in ongoing/planned RCTs of 
various primary prevention modalities (e.g., condoms, microbicides, behavior change) for 
prevention of HIV and /or other STD. (High priority) 
b.	 Because of the limited confidence in condoms for prevention of genital HPV infection, 
studies of behavior change (e.g., reduction in number of partners, selection of less sexually 
experienced partners, and delayed onset of intercourse, and which focus in part on the high 
prevalence and relative difficulty of preventing HPV infection) to prevent HPV outcomes 
should be considered. Although it was recognized that such studies would be difficult to 
perform and could have the unintended consequence of increasing the stigma and anxiety 
associated with HPV infection, they could also have other STD prevention benefits. These 
studies would also need to address the potential of such behavior change approaches to 
undermine condom use, possibly enhancing acquisition of STD (e.g., HIV, gonorrhea) 
more effectively prevented by condom use. (High priority) 
c.	 Additional studies of the role of treatment in preventing transmission should be performed 
including assessment of persistence of detectable HPV DNA after treatment of GW and SIL. 
(Intermediate priority) 
d.	 In order to inform patient counseling (especially as HPV testing becomes more common), 
transmission modelling, and intervention assessment/planning, studies to better define lab­
oratory markers of genital HPV infectivity (e.g., viral load, mRNA detection, viral capsid 
protein detection, etc.) in different anatomic sites and lesion types should be performed. 
(Intermediate priority) 
e.	 Additional studies of risk factors of persistent HPV infection should be performed because 
of the potential role of persistent infection in transmission dynamics in women and men, as 
well as in predicting subsequent neoplasia. (Intermediate priority). 
4.	 Preparedness for prophylactic HPV vaccines 
Background 
The difficulty with non-vaccine modalities of primary prevention and the large global burden of 
HPV-related disease make the development of effective prophylactic vaccines an important public 
health priority32. Initial barriers to development of promising candidate HPV vaccines included the 
difficulties in propagating the virus in vitro, the potential hazard of a vaccine containing an 
oncogenic viral genome, and the lack of an animal model of HPV infection suitable for challenge 
experiments32, 146-148. The development of L1 virus-like particle (VLP) subunit vaccines through mo­
lecular biologic techniques has remedied the first two problems. L1, the major capsid protein and 
the site of the primary neutralizing epitopes of HPV, self-assembles into particles resembling 
authentic virions after expression in eukaryotic cells, thus retaining the native conformation 
required for induction of neutralizing antibody. The lack of an animal model for studying HPV 
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remains an issue, although challenge studies with species-specific papillomaviruses and parenteral 
injection of VLPs have demonstrated a consistently high level of protection (90-100%) against 
infection in three animal systems, one cutaneous (cottontail rabbit PV) and two oral mucosal 
(bovine PV type 4 and canine oral PV)146. These results have stimulated great enthusiasm about the 
potential of VLP vaccines to prevent infection in humans. Several Phase I trials sponsored by 
industry and by the NIH with monovalent HPV 6, 11, and 16 VLP vaccines are underway, with 
subsequent larger clinical trials likely if the initially promising immunogenicity and safety results are 
confirmed32, 147 . 
Although there is cause for optimism about the potential value of VLPs as prophylactic HPV 
vaccines, several important issues remain to be addressed. First, the animal challenge studies, 
although encouraging, have not used natural routes of mucosal infection, and vaccination 
strategies which produce greater levels of mucosal immunity may ultimately be required to prevent 
human infection. Second, while trials of monovalent vaccines are appropriate for initial proof of 
concept studies, polyvalent vaccines will ultimately be preferable because of the large number of 
HPV types found in cervical cancer and genital warts and the apparent lack of cross-type immunity 
produced by L1 vaccines, adding to the time required for full evaluation. Third, cervical cancer will 
not be a feasible endpoint to study because of its long latency, and clinical trials will need to focus on 
shorter-term (and more indirect for cancer prevention) measures such as HPV infection and CIN. 
Fourth, initial studies will need to be conducted in females in order to assess CIN outcomes and 
while studying those without prior genital HPV exposure is desirable, trials may need to focus on 
young adults rather than adolescents for ethical reasons. This presents an issue of translating clinical 
trials into practice, since the ideal target for an STD with a high incidence soon after onset of sexual 
activity would be pre-sexually active adolescents or children, including males as well as females. Ul­
timately, a vaccine which has therapeutic value in early infection as well as prophylactic value would 
be optimal, providing benefit to those who are already infected as well as those uninfected; this may 
allow a greater flexibility of populations who could be targeted, and thus possibly earlier public 
health benefit in terms of cancer prevention32, 147, 148. 
Workgroup discussion 
Effective HPV vaccines would represent a major public health advance and their development 
was strongly endorsed by experts across multiple disciplines as a high priority research initiative. 
The workgroup participants thought that industry and the NIH should continue to play the primary 
role in developing new candidate vaccines and assessing their efficacy in clinical trials. In addition, 
there are a number of important issues which will need to be addressed both prior to as well as fol­
lowing licensure of effective vaccines which might appropriately involve CDC or other organiza­
tions interested in prevention of genital HPV infection. Several issues were felt to be important for 
upcoming clinical trials. Of immediate concern was a better understanding of the incidence and nat­
ural history of HPV infection in men, since they will likely be included in clinical trials at some point. 
Also, because serologic measures of incident infection are insensitive and, after VLP immunization, 
nonspecific for natural infection versus vaccine response, another priority of relevance for clinical 
trials is development of cheaper and less intrusive methods to establish incident HPV infection 
through samples collected from mucosal surfaces in order to permit less costly and more frequent 
assessment of outcomes. Additional issues would become important if initial trials indicated the 
likelihood of vaccine efficacy. For example, because cost analyses have been important in driving 
other vaccine implementation efforts and also in influencing pricing decisions, cost-effectiveness 
studies of vaccines for both high-risk and low-risk types of HPV would be useful and could lead to 
collection of specific cost data during final trials in order to refine analyses. Also, transmission mod­
eling studies could help assess the level of vaccine efficacy required for a population-based 
benefit149 and could also be of value in assessing different age and gender mixes in vaccine imple­
mentation strategies. Of particular concern are issues of gaining acceptance among the general 
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public and healthcare providers for an HPV vaccine. The experience with hepatitis B immunization, 
the only STD for which an effective vaccine exists, showed that implementation was limited in the 
general population until a universal immunization approach was recommended, and even with 
hepatitis B, because of other routes of transmission, the “STD connection” has not been empha­
sized. The workgroup felt that effective ways of presenting an HPV vaccine to the public, including 
parents who would need to consent if the vaccine were administered to minors not yet sexually ac­
tive, and also to providers need to be explored, preferably in collaboration with industry. These as­
sessments should include whether the vaccine is best described as one to prevent a common STD, 
which would be applicable to both females and males, versus a vaccine to prevent cancer, which 
would be largely relevant for females. 
Research/evaluation priorities 
a.	 More extensive population-based studies should be performed of rates and risk factors for 
genital and anal HPV incidence, prevalence, and persistence in men. These studies should 
include adolescent and young adult heterosexuals as well as men who have sex with men 
(MSM) and should be conducted in both developed and developing countries. (High 
priority) 
b.	 Improved sampling and testing methods are needed to detect incident genital HPV 
infection as a study outcome, including assays sensitive enough to detect HPV infections in 
men, sensitive and specific methods to detect type-specific (and quantitative) HPV 
infection, and methods amenable to self-sampling (to allow more frequent and less expen­
sive measurements of outcomes). (High priority) 
c.	 Given that there is no experience with implementing immunization programs for infections 
transmitted predominantly by sexual activity, marketing research about HPV vaccine 
acceptability in adolescents, their parents, and their health care providers should be 
encouraged by and/or carried out by CDC. (High priority) 
d.	 Mathematical modeling studies of genital HPV transmission should be performed in order 
to assess optimal targets for immunization programs (e.g., age and gender mix). (High 
priority) 
e.	 Cost-effectiveness studies of HPV vaccines should be carried out from a societal perspec­
tive, including assessment of indirect and intangible costs. These should include studies of 
HPV 6/11 to further encourage industry efforts to develop and test vaccines for these types, 
both as a means of preventing their sequelae (e.g., genital warts, CIN 1, and recurrent respi­
ratory papillomatosis) in women as well as to offer benefit to men. (High priority) 
f.	 Studies of alternative, potentially more convenient routes of delivery and dosing schedules 
of HPV vaccines should be conducted. (High priority) 
g.	 Following successful efficacy trials of HPV vaccines in young adult women, immunogenicity 
studies should be performed in other populations (e.g., heterosexual men and MSM, young 
adolescent men and women, higher risk patients such as those attending STD clinics). (High 
priority) 
h.	 Following licensure of an effective vaccine, studies should be performed to assess behav­
ioral implications of its use (e.g., increases in risky sexual behavior due to misperceptions 
about vaccine protection against other STD, reduced compliance with cancer screening rec­
ommendations, etc.). (Intermediate priority) 
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5. Provider, patient, and public awareness 
Background 
Improvement in awareness by health care providers and the general public has been an impor­
tant strategy in response to widespread public health problems such as HIV infection. Greater pro­
vider understanding can improve management of patients and provision of information to them 
and their families (or partners in the case of STD), and awareness in the general public can enhance 
responsiveness to prevention activities, such as screening or immunization. Data on provider un­
derstanding about genital HPV infection are limited. They suggest that providers are broadly aware 
of the sexually transmitted nature of the infection and its relationship to cervical cancer, but are less 
clear about the relationship of genital warts to cancer, the indication for use of various management 
strategies, transmission-related issues, and the indications for partner evaluation150-152. This lack of 
clarity, coupled with discomfort over discussion of issues related to STD and sexuality and limited 
time for counseling/education, is often perceived by patients as inadequate information and 
advice152-154. Limited data from selected populations show substantial levels of emotional distress 
among patients with a diagnosis of genital HPV infection (genital warts or abnormal Pap smears), 
which can far exceed the level of physical distress. These include feelings of shock, shame, anger at 
partners and providers, depression, and fear about sequelae and ongoing contagiousness152, 153, 
155-157. Fear of or actual experience of rejection in future sexual relationships was reported by 67% 
and 19% of patients, respectively153. 
Workgroup discussion 
The workgroup felt that the awareness of cervical cancer and of Pap smear screening as a preven­
tion strategy are widely recognized and supported by the general public in the U.S. However, the 
linkage of genital HPV infection to cervical cancer is much less widely recognized, and understand­
ing of genital HPV as an STD is limited, with STD awareness only slightly greater among women 
with multiple partners than other women154. Promoting public awareness in these areas is 
appealing, but represents a complex situation. On the one hand, a policy of consistently informing 
the public about strongly documented scientific findings is likely to be the most ethical and effective 
policy in the long run, and may help to lessen stigma and increase sympathy for persons suffering 
from sequelae of STDs. Such messages could also be useful in enhancing future acceptance of HPV 
immunization programs32. Furthermore, STD prevention messages that have been underutilized to 
date because of concerns over their likely benefit (e.g., reducing the number of sex partners and 
choosing safer sex partners) might become more acceptable strategies for many individuals if there 
were greater awareness of the magnitude of genital HPV infection. 
On the other hand, promotion of greater awareness that cervical cancer is linked to an STD could 
conceivably undermine general support for Pap smear screening programs or could lead women or 
providers to decide that a woman considered to be at low risk for an STD does not need a Pap 
smear. Directing prevention messages to the general public is further complicated by the lack of 
clarity of what the most appropriate health care and prevention strategies are for HPV infection, 
given that most infected persons are asymptomatic, the overwhelming majority will not suffer any 
adverse consequences, no data document that condoms are effective for HPV prevention, diagnos­
tic services are relatively expensive, and diagnosis of HPV infection has not yet been demonstrated 
to lead to improvement in health outcomes. Therefore, it may be counterproductive to promote 
messages that increase anxiety in the absence of effective strategies to reduce risk for infection. The 
workgroup emphasized that messages must be carefully crafted to deal with these complexities and 
that assessment of such prevention messages should be a critical element of research. Audiences 
must at least be segmented into providers, persons with known HPV infection, and the general 
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population. When messages are directed to patients or to the general public, it is important that par­
allel efforts be made to inform providers at same time. 
Provider awareness 
Recommendations for public health/prevention activities 
CDC, ACS, and other organizations interested in prevention of genital HPV infection and 
sequelae should draft a consensus statement for use in professional educational materials of what 
has been scientifically established about HPV (as well as what is not known). This statement should 
address currently available diagnostic, treatment, prevention, and counseling/education strategies 
and should be widely disseminated (e.g., published, put on websites, etc) and updated on a regular 
basis. 
Research/evaluation priorities 
Although methodologically challenging, surveys of provider knowledge, attitudes, and practices 
should be conducted to guide future targeting of educational efforts. (Intermediate priority) 
Patient awareness 
Recommendations for public health/prevention activities 
In conjunction with development of professional educational materials, patient educational 
materials should be developed and distributed widely, and their use and/or adaptation by groups 
involved in patient education strongly encouraged. 
Research/evaluation priorities 
a.	 Efforts should be made to assess counseling/educational needs for patients (and partners) 
with HPV-related diagnoses and to develop alternatives to physicians as primary providers 
of education/counseling. These might include other types of patient educators (e.g., nurse 
clinicians who provide diabetes education, which is now a billable non-physician service), 
brochures, web-based material, hotlines, etc. (High priority) 
b.	 Studies should be performed on the behavioral/psychosocial impact of HPV-related diag­
noses on persons with genital warts and CIN and their partners and the impact of disclosure 
about these conditions on current and future sexual partnerships. (Intermediate priority) 
Public awareness 
Research/evaluation priorities 
a.	 Knowledge and attitude surveys should be performed to assess information needs of vari­
ous populations within the general public and to help guide existing and possible future 
public awareness activities. (Intermediate priority) 
b.	 Pilot public education programs should be carried out in selected areas to assess optimal 
form and content of public awareness messages as well as potential drawbacks (e.g., stig­
matization of Pap smear screening programs, competition with other public health preven­
tion messages), both to respond to the increased public concern likely to occur with wider 
use of HPV testing and also to enhance prevention activities related to HPV and sequelae 
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(i.e., Pap smear screening, vaccine preparedness, general understanding of relationship of 
HPV to cervical cancer) . (High priority) 
6. Anal Cancer 
Background 
Anal cancer is a relatively uncommon malignancy, with a current U.S. incidence rate of only 0.9/ 
100,00033. However, incidence rates are reported to have increased over the past 20-30 years in 
several countries19, 33, 34, 158, including the U.S., where rates increased by 96% for men and 39% for 
women from 1973-9733. This increase has been partly ascribed to changes in sexual activity. There 
is a growing body of data linking anal cancer to sexual behavior, especially anal intercourse, and 
HPV infection19, 159, 160. The highest incidence is reported in MSM, with rates 12 to 50 times higher 
than in heterosexual men159-162 and an overall annual incidence rate of up to 35/100,000159, similar 
to rates of cervical cancer among women in the absence of Pap smear screening163. Women with 
previous cervical cancer are also at higher risk for anal cancer, an association likely attributable to 
the presence of HPV infection at both sites164. 
An additional factor in this increase may be the HIV epidemic. Prevalence rates of anal SIL (ASIL) 
of 20-45% have been reported in HIV+ MSM, substantially higher than in HIV- MSM, with ASIL 
most strongly correlated with HPV infection163, 165-168. Two prospective studies have documented a 
higher incidence of anal HSIL lesions in HIV+ vs. HIV- men, with incident HSIL associated with 
persistent HPV infection in both HIV+ and HIV- men166, 168. Finally, rates of anal cancer are esti­
mated to be 30-80 fold higher in patients with AIDS than in the general population, although the 
proportion of this increase attributable to the higher overall rates seen in MSM versus the effect of 
HIV-related immunodeficiency has not been determined162, 167, 169. These data have lead to consid­
eration of the potential benefit of anal cancer prevention programs163, 170, 171 through cytologic 
screening, since evaluations to date suggest that anal Pap smears may be similar in sensitivity to 
cervical smears172, 173. This approach is supported by modeling studies of anal cancer screening in 
MSM, which indicate that the cost-effectiveness of screening could be similar to that for other 
prevention interventions. However, the models are most sensitive to assumptions about the natural 
history of anal LSIL, about which there are limited data, and the natural history of HSIL and the 
effectiveness of ablative therapy, about which there are virtually no data35, 174. Furthermore, little is 
known about the complications of ablative treatment, either in terms of medical costs or effect on 
quality of life. An additional consideration is the uncertain impact of the use of highly active 
antiretroviral therapy in HIV+ MSM, in that it could possibly lead to either an increased risk of anal 
cancer owing to greater longevity or a reduced risk owing to better control of HPV infection and 
regression of SIL lesions as a result of improved immune function175. 
Workgroup discussion 
Despite the relative infrequency of anal cancer at the population level, the workgroup thought 
that pursuing prevention strategies for high-risk groups (primarily HIV+ MSM, but also HIV+ 
women and HIV- MSM) was important, and that studies to obtain better information about natural 
history and effectiveness of treatment of anal SIL lesions were high priorities. There were differences 
of opinion on how best to conduct these studies. On the one hand, because so many key questions 
about a potentially important prevention strategy remain unanswered and because lack of wide­
spread implementation of anal cancer screening programs to date mean that “standards of care” 
have not been established, most of the workgroup felt that it would be ethical and appropriate for 
these studies to be implemented as RCTs. Such studies could provide much-needed unbiased data 
on rates of progression and regression of HSIL, and if follow-up were performed at close intervals, 
could minimize the risk of those anal cancers which did occur developing beyond an early stage. 
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Likewise, they could provide the best information on the effectiveness and complications associ­
ated with ablative therapy. On the other hand, there was also an opinion that, because of the biolog­
ically plausible analogy with the cervix and the risk of untreated HSIL progressing to cancer, it would 
be ethically problematic not to offer therapy to those with such lesions. An alternative evaluation 
methodology could thus involve a demonstration project of anal cancer screening, with follow-up of 
those electing no treatment for HSIL to assess natural history and of those choosing treatment to 
assess efficacy and complications of therapy. This approach would also provide the opportunity to 
assess operational feasibility and training needs of an anal cancer screening program and help to 
further refine cost-effectiveness analyses. 
Research/evaluation priorities 
a.	 Multicenter projects (RCTs or demonstration projects) should be initiated to assess parame­
ters of importance in anal cancer screening programs in MSM, especially a better under­
standing of the natural history of LSIL and HSIL in HIV+ and HIV- MSM and the efficacy 
and complications of ablative therapy of anal HSIL in HIV+ and HIV- MSM. (High priority) 
b.	 Studies should be performed to determine reproducibility, interobserver variability, optimal 
sampling technique, and predictive value of anal Pap smears. (High priority) 
c.	 Analogous to studies of cervical cancer prevention, studies should be performed to evaluate 
performance of HPV testing in triage of abnormal anal Pap smears and in primary screen­
ing. (Intermediate priority) 
d.	 Studies should be performed to determine risk factors for women and heterosexual men 
with anal cancer as a possible guide to future screening programs. (Intermediate priority) 
7.	 Surveillance for genital HPV infection and sequelae 
Background 
The term “surveillance” in public health encompasses a range of activities. Surveillance for STDs 
in the U.S. includes three categories of activities: case notification (e.g., reporting of individual 
cases of notifiable conditions by providers or laboratories), prevalence monitoring (e.g., monitoring 
the prevalence of infection in settings where screening occurs systematically), and other special 
studies (e.g., sentinel surveillance activities, supplemental testing which may provide information 
about the incidence or prevalence of an STD). To avoid unnecessary workloads for providers and 
laboratories, case notification is recommended for STD with case management implications (e.g., 
curative treatment, partner notification), with planned or ongoing prevention programs (e.g., 
screening, immunizations), or in the setting of an outbreak. Case notification of STDs for these pur­
poses is currently recommended nationally by the Council of State and Territorial Epidemiologists 
(CSTE) only for syphilis, gonorrhea, chlamydia, hepatitis B, and chancroid. All three categories of 
surveillance activity are reflected in current U.S. surveillance data for STDs176. 
HPV infections and their sequelae pose many challenges for routine public health surveillance ef­
forts. The estimated number of new infections with genital HPV is substantially higher than those of 
the reportable STD1, and they are largely undiagnosed given the limitations of routine diagnostics. 
Although there have been no national recommendations encouraging case notification of HPV in­
fection, a number of states have made genital warts a reportable condition. Preliminary analysis of 
these reports indicate that they did not provide representative data since the vast number came 
from public clinics and were of warts in men, despite the widespread occurrence of genital warts in 
women (DSTD, unpublished observations). Special surveillance studies for genital HPV infection 
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include assessment through the National Disease and Therapeutic Index (NDTI) of the number and 
proportion of ambulatory care visits in the U.S. accounted for by genital warts176, a sentinel surveil­
lance system for RRP37, and a population-based national household survey, the National Health 
and Nutrition Examination Survey (NHANES), which has provided valuable information about 
trends in infection with genital herpes177 and from which pilot seroprevalence surveys for HPV 16 
and 6/11 are planned. 
At the other end of the natural history spectrum, surveillance for cervical and other anogenital 
cancers is through cancer registries. National cancer surveillance in the U.S. has been carried out 
through the NIH National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) 
Program since 1973, comprising 11 geographic areas covering about 14% of the U.S. population. 
Extrapolations from these data are used to determine rates and trends in various types of cancers 
and are also the basis for annual estimates of cancer incidence compiled by the American Cancer 
Society. To supplement data collected through SEER on a broader geographic basis, CDC initiated 
the National Program of Cancer Registries (NPCR) in 1992, which will cover over 95% of the popu­
lation when fully operational. 
Workgroup discussion 
The workgroup concluded that at the current time public health surveillance for genital HPV in­
fection is best done through prevalence monitoring and special studies rather than through case re­
porting, because of the absence of the rationale for such as discussed above. There was discussion 
about a range of potential new surveillance activities for HPV infection and related sequelae in the 
U.S., focusing particularly on events in the natural history of HPV infection that are intermediate be­
tween first acquisition of infection at one extreme, and diagnosis of cancer at the other extreme. For 
high-risk HPV types, such events might include: development of persistent genital HPV infection, 
given its association with development of CIN; detection of serologic evidence of type-specific in­
fection, given its association with persistent mucosal infection25; and detection of cervical 
carcinoma in situ (CIS). There was consensus that CIS, as the most advanced pre-cancerous 
precursor lesion, would be extremely useful to follow at a population-based level as an early 
indicator of the impact of an HPV immunization program. It was noted that since this diagnosis is in­
creasingly made in outpatient settings, it had become difficult to capture through traditional cancer 
registry programs which focus on hospital-based care, and that because of this problem, the SEER 
Program had recently chosen to discontinue collection of this diagnosis. Suggestions about 
alternative systems, albeit not population-based, from which to collect data on rates of CIS include 
sentinel surveillance within managed care organizations or the Indian Health Service. For low-risk 
HPV types, key events for surveillance include not only genital warts, which may be possible to track 
through clinic-based and administrative datasets more effectively than is currently the case through 
NDTI, but also juvenile-onset RRP, which is as common as neonatal herpes infection but much less 
widely recognized. 
Recommendations for public health/prevention activities 
a.	 Routine disease reporting (e.g., case notification) of all genital HPV infections or of any spe­
cific HPV disease or type (e.g., genital warts, HPV 16 infection) is not practical and thus not 
recommended at this time. 
b.	 CDC should conduct further analysis of the experience with genital warts reporting in vari­
ous states to guide future directions in genital warts surveillance. Although data from the 
NDTI have limitations, their continued analysis by CDC is recommended until superior 
data, preferably population-based, become available. 
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c.	 Routine reporting of CIS could represent a valuable adjunct to cancer surveillance, espe­
cially as HPV immunization programs are implemented. However, because of past prob­
lems encountered by SEER, future efforts to report and interpret data on CIS should 
examine this experience and consider alternative approaches to monitor this diagnosis. 
d.	 Surveillance for HPV-related cancers should be enhanced in ways that contribute to 
understanding the causative role of HPV infections and to prevention strategies. Such 
enhancements could include recording the sexual preference of men with anogenital 
cancers (recognizing that this will depend upon the consistency with which this variable is 
recorded in the medical record). 
Research/evaluation priorities 
a.	 Pilot NHANES seroprevalence studies by CDC should be continued and other 
subpopulations for similar studies should be identified, since monitoring serologic evidence 
of infection with HPV 16 and/or other high risk types may be an efficient method of 
prevalence monitoring. These studies should also be expanded to include self-collected 
samples such as vaginal swabs and urine samples for HPV DNA studies, with a focus on 
specific types likely to be included in vaccines, since these may enhance data provided by 
serologic studies in monitoring levels of type-specific infection over time. (High priority) 
b.	 A sentinel approach, possibly in areas where other sentinel surveillance activities (e.g., 
SEER or one of the NPCR sites) have been established, should be considered in order to 
evaluate the spectrum and trends of HPV-related disease and as a foundation for 
subsequent population-level prevention activities such as immunization programs. Such 
activities might include monitoring specific types and type-variants of HPV infection and 
population-based Pap smear registries. (High priority) 
c.	 The current CDC sentinel surveillance for juvenile-onset RRP should be strengthened and 
expanded (e.g., additional sites; more data related to acquisition of infection, including ma­
ternal HPV status and other risk factors for mother-child transmission; consideration of case 
control and/or observational studies to better define risk factors for transmission and poten­
tial benefit of interventions such as C-section). (High priority) 
d.	 Because ICD and CPT codes do not accurately capture HPV-related diagnoses, treatments, 
or procedures, CDC should explore efforts to redefine these codes. Such changes would 
enhance prevalence monitoring of HPV-related outcomes and ongoing assessments of 
HPV-related healthcare costs in large administrative databases (e.g., Medicaid, Medstat, 
etc.). (Intermediate priority) 
e.	 CDC should make efforts to collaborate with organizations that have electronic databases 
of patient encounters which include variables such as reason for visit and primary 
diagnosis (e.g., STD clinics, group model HMOs, etc.) in order to monitor trends in and as­
sess burden of health care related to the prevalence of genital warts. (Intermediate priority) 
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